An economic evaluation of antihypertensive therapies based on clinical trials

Detalhes bibliográficos
Autor(a) principal: Tsuji, Rosana Lima Garcia
Data de Publicação: 2012
Outros Autores: Silva, Giovanio Vieira da, Ortega, Katia Coelho, Berwanger, Otavio, Mion Júnior, Decio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/19700
Resumo: OBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure (in mm Hg) at the end of a 12-month study period. RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the same pattern when the purchase price of the lower-cost medication was used. CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and the current treatment for the HT3 group.
id USP-19_d41a2eafbeda78c36c1cfe96594856bf
oai_identifier_str oai:revistas.usp.br:article/19700
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling An economic evaluation of antihypertensive therapies based on clinical trialsHypertensionPharmacoeconomicsCost-effectivenessAntihypertensive drugsOBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure (in mm Hg) at the end of a 12-month study period. RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the same pattern when the purchase price of the lower-cost medication was used. CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and the current treatment for the HT3 group.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1970010.6061/clinics/2012(01)07Clinics; Vol. 67 No. 1 (2012); 41-48Clinics; v. 67 n. 1 (2012); 41-48Clinics; Vol. 67 Núm. 1 (2012); 41-481980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/19700/21764Tsuji, Rosana Lima GarciaSilva, Giovanio Vieira daOrtega, Katia CoelhoBerwanger, OtavioMion Júnior, Decioinfo:eu-repo/semantics/openAccess2012-05-24T19:09:29Zoai:revistas.usp.br:article/19700Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-24T19:09:29Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv An economic evaluation of antihypertensive therapies based on clinical trials
title An economic evaluation of antihypertensive therapies based on clinical trials
spellingShingle An economic evaluation of antihypertensive therapies based on clinical trials
Tsuji, Rosana Lima Garcia
Hypertension
Pharmacoeconomics
Cost-effectiveness
Antihypertensive drugs
title_short An economic evaluation of antihypertensive therapies based on clinical trials
title_full An economic evaluation of antihypertensive therapies based on clinical trials
title_fullStr An economic evaluation of antihypertensive therapies based on clinical trials
title_full_unstemmed An economic evaluation of antihypertensive therapies based on clinical trials
title_sort An economic evaluation of antihypertensive therapies based on clinical trials
author Tsuji, Rosana Lima Garcia
author_facet Tsuji, Rosana Lima Garcia
Silva, Giovanio Vieira da
Ortega, Katia Coelho
Berwanger, Otavio
Mion Júnior, Decio
author_role author
author2 Silva, Giovanio Vieira da
Ortega, Katia Coelho
Berwanger, Otavio
Mion Júnior, Decio
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Tsuji, Rosana Lima Garcia
Silva, Giovanio Vieira da
Ortega, Katia Coelho
Berwanger, Otavio
Mion Júnior, Decio
dc.subject.por.fl_str_mv Hypertension
Pharmacoeconomics
Cost-effectiveness
Antihypertensive drugs
topic Hypertension
Pharmacoeconomics
Cost-effectiveness
Antihypertensive drugs
description OBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure (in mm Hg) at the end of a 12-month study period. RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the same pattern when the purchase price of the lower-cost medication was used. CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and the current treatment for the HT3 group.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19700
10.6061/clinics/2012(01)07
url https://www.revistas.usp.br/clinics/article/view/19700
identifier_str_mv 10.6061/clinics/2012(01)07
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19700/21764
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 67 No. 1 (2012); 41-48
Clinics; v. 67 n. 1 (2012); 41-48
Clinics; Vol. 67 Núm. 1 (2012); 41-48
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222758267781120